Argonaute 2 Promotes Myeloma Angiogenesis Via MicroRNA Dysregulation

Overview

Journal J Hematol Oncol

Publisher Biomed Central

Specialties Hematology
Oncology

Date 2014 Jun 3

PMID 24886719

Citations 25

Authors

Shuang Wu

Wenjun Yu

Xiaoyan Qu

Rong Wang

Ji Xu

Qiguo Zhang

Jiaren Xu

Jianyong Li

Lijuan Chen

Affiliations

Soon will be listed here.

Abstract

Background: Dysregulated microRNA (miRNA) expression contributes to cancer cell proliferation, apoptosis and angiogenesis. Angiogenesis is a hallmark of multiple myeloma (MM) development and progression. Argonaute 2 (AGO2) protein, a core component of the RNA-induced silencing complex (RISC), can directly bind to miRNAs and mediate target messenger RNA (mRNA) degradation. A previous study showed that AGO2 knockdown suppressed human umbilical vein endothelial cell (HUVEC) growth and tube formation. However, the roles and molecular mechanisms of AGO2-induced myeloma angiogenesis are not yet fully understood. The aim of this study was to characterize these roles and effects and their associated mechanisms.

Results: Supernatants from AGO2-overexpressing MM lines induced HUVEC migration and accelerated tube formation. Conversely, supernatants from AGO2-knockdown MM lines suppressed HUVEC cell migration and tube formation. Moreover, a chick chorioallantoic membrane (CAM) assay was used to demonstrate that AGO2 could drive neovessel formation in MM lines in vivo. Using an miRNA microarray, we observed that 25 miRNAs were upregulated and 7 were downregulated in response to AGO2. Most let-7 family members and 2 miR-17/92 cluster members (miR-17a and miR-92-1), all known pro-angiogenic miRNAs, were positively regulated by AGO2 whereas anti-angiogenic miRNAs such as miR-145 and miR-361 were negatively regulated by AGO2.

Conclusions: We conclude that AGO2 can drive neovessel formation in vitro and in vivo by dysregulating the expression of some angiogenic miRNAs. The pro-angiogenic miRNAs of the let-7 family and the miR-17/92 cluster, along with the anti-angiogenic miRNA miR-145, play crucial roles in AGO2-mediated angiogenesis by targeting angiogenesis-related genes.

Citing Articles

Comprehensive Analysis Identifies Hsa_circ_0058191 as a Potential Drug Resistance Target in Multiple Myeloma.

Yang H, Zhu J, Wang X Onco Targets Ther. 2025; 18:225-231.

PMID: 39963489 PMC: 11831480. DOI: 10.2147/OTT.S505074.

Argonaute 2 Restores Erectile Function by Enhancing Angiogenesis and Reducing Reactive Oxygen Species Production in Streptozotocin (STZ)-Induced Type-1 Diabetic Mice.

Liu F, Yin G, Ock J, Fridayana F, Niloofar L, Huang Y Int J Mol Sci. 2023; 24(3).

PMID: 36769259 PMC: 9918048. DOI: 10.3390/ijms24032935.

Serum proteomic profiling reveals MTA2 and AGO2 as potential prognostic biomarkers associated with disease activity and adverse outcomes in multiple myeloma.

Apipongrat D, Roytrakul S, Prayongratana K, Charoenpitakchai M, Intharanut K, Laoruangroj C PLoS One. 2022; 17(12):e0278464.

PMID: 36454786 PMC: 9714744. DOI: 10.1371/journal.pone.0278464.

p63, a key regulator of Ago2, links to the microRNA-144 cluster.

Wang B, Wu H, Abuetabh Y, Leng S, Davidge S, Flores E Cell Death Dis. 2022; 13(4):397.

PMID: 35459267 PMC: 9033807. DOI: 10.1038/s41419-022-04854-1.

Microvascular Experimentation in the Chick Chorioallantoic Membrane as a Model for Screening Angiogenic Agents including from Gene-Modified Cells.

Kennedy D, Coen B, Wheatley A, McCullagh K Int J Mol Sci. 2022; 23(1).

PMID: 35008876 PMC: 8745510. DOI: 10.3390/ijms23010452.

References

Hatanaka K, Shimizu K, Asai T, Oku N . [Antineovascular gene therapy by Ago2 knockdown]. Yakugaku Zasshi. 2008; 128(11):1567-75. DOI: 10.1248/yakushi.128.1567. View

Tageja N . Lenalidomide - current understanding of mechanistic properties. Anticancer Agents Med Chem. 2011; 11(3):315-26. DOI: 10.2174/187152011795347487. View

Zhang X, Graves P, Zeng Y . Overexpression of human Argonaute2 inhibits cell and tumor growth. Biochim Biophys Acta. 2012; 1830(3):2553-61. DOI: 10.1016/j.bbagen.2012.11.013. View

Hagiwara K, Kosaka N, Yoshioka Y, Takahashi R, Takeshita F, Ochiya T . Stilbene derivatives promote Ago2-dependent tumour-suppressive microRNA activity. Sci Rep. 2012; 2:314. PMC: 3304512. DOI: 10.1038/srep00314. View

Zhou Y, Chen L, Barlogie B, Stephens O, Wu X, Williams D . High-risk myeloma is associated with global elevation of miRNAs and overexpression of EIF2C2/AGO2. Proc Natl Acad Sci U S A. 2010; 107(17):7904-9. PMC: 2867889. DOI: 10.1073/pnas.0908441107. View

Pichiorri F, Suh S, Ladetto M, Kuehl M, Palumbo T, Drandi D . MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis. Proc Natl Acad Sci U S A. 2008; 105(35):12885-90. PMC: 2529070. DOI: 10.1073/pnas.0806202105. View

Doebele C, Bonauer A, Fischer A, Scholz A, Reiss Y, Urbich C . Members of the microRNA-17-92 cluster exhibit a cell-intrinsic antiangiogenic function in endothelial cells. Blood. 2010; 115(23):4944-50. DOI: 10.1182/blood-2010-01-264812. View

Shaughnessy Jr J, Zhan F, Burington B, Huang Y, Colla S, Hanamura I . A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood. 2006; 109(6):2276-84. DOI: 10.1182/blood-2006-07-038430. View

Keeley E, Mehrad B, Strieter R . CXC chemokines in cancer angiogenesis and metastases. Adv Cancer Res. 2010; 106:91-111. PMC: 3069502. DOI: 10.1016/S0065-230X(10)06003-3. View

10.

Mayani H . Hematopoietic and microenvironment alterations in bone marrow from patients with multiple myeloma. Leuk Res. 2012; 37(2):228-9. DOI: 10.1016/j.leukres.2012.11.012. View

11.

Nelson K, Weiss G . MicroRNAs and cancer: past, present, and potential future. Mol Cancer Ther. 2008; 7(12):3655-60. DOI: 10.1158/1535-7163.MCT-08-0586. View

12.

Guo D, Li C, Teng Q, Sun Z, Li Y, Zhang C . Notch1 overexpression promotes cell growth and tumor angiogenesis in myeloma. Neoplasma. 2012; 60(1):33-40. DOI: 10.4149/neo_2013_005. View

13.

Iorio M, Ferracin M, Liu C, Veronese A, Spizzo R, Sabbioni S . MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 2005; 65(16):7065-70. DOI: 10.1158/0008-5472.CAN-05-1783. View

14.

Dhanabal M, Jeffers M, LaRochelle W, Lichenstein H . Angioarrestin: a unique angiopoietin-related protein with anti-angiogenic properties. Biochem Biophys Res Commun. 2005; 333(2):308-15. DOI: 10.1016/j.bbrc.2005.05.134. View

15.

Harvey R, Lonial S . PI3 kinase/AKT pathway as a therapeutic target in multiple myeloma. Future Oncol. 2007; 3(6):639-47. DOI: 10.2217/14796694.3.6.639. View

16.

Augstein A, Poitz D, Braun-Dullaeus R, Strasser R, Schmeisser A . Cell-specific and hypoxia-dependent regulation of human HIF-3α: inhibition of the expression of HIF target genes in vascular cells. Cell Mol Life Sci. 2010; 68(15):2627-42. PMC: 11115058. DOI: 10.1007/s00018-010-0575-4. View

17.

Moehler T . Clinical experience with thalidomide and lenalidomide in multiple myeloma. Curr Cancer Drug Targets. 2012; 12(4):372-90. DOI: 10.2174/156800912800190893. View

18.

Ender C, Meister G . Argonaute proteins at a glance. J Cell Sci. 2010; 123(Pt 11):1819-23. DOI: 10.1242/jcs.055210. View

19.

Manier S, Sacco A, Leleu X, Ghobrial I, Roccaro A . Bone marrow microenvironment in multiple myeloma progression. J Biomed Biotechnol. 2012; 2012:157496. PMC: 3471001. DOI: 10.1155/2012/157496. View

20.

Gao X, Zhang R, Qu X, Zhao M, Zhang S, Wu H . MiR-15a, miR-16-1 and miR-17-92 cluster expression are linked to poor prognosis in multiple myeloma. Leuk Res. 2012; 36(12):1505-9. DOI: 10.1016/j.leukres.2012.08.021. View